Cell and Gene Therapy Manufacturing Market Size & Share to Surpass $15.4 Billion by 2030
The Global Cell and Gene Therapy Manufacturing Market, as reported by Vantage Market Research, has been experiencing consistent growth owing to technological advancements, enhanced investment in R&D, and the capacity of these therapies to transform healthcare through personalized treatments.
Market Value Projections:
Estimated value by 2030: USD 15.4 Billion
Growth from 2022 to 2023: From USD 4.8 Billion to an 18.2% CAGR till 2030
Understanding Cell and Gene Therapy Manufacturing:
Cell and gene therapy manufacturing involves producing therapeutic products using living cells or gene editing. Techniques such as stem cell therapies, CAR-T cell therapies, and other state-of-the-art treatments fall under this manufacturing process.
Key Data Points:
Therapy Type: Cell Therapy manufacturing led the market with a 60.1% revenue share in 2022.
Application: Commercial-scale manufacturing is expected to see the highest CAGR.
Indication: Oncology-related diseases project the highest CAGR.
End-User: Pharmaceutical & Biotechnology Companies are likely to experience the highest growth rate.
Geographical Distribution: North America led with a 48.20% revenue share in 2022.
Cell and gene therapies are being utilized and researched across numerous areas like cancer, genetic disorders, and autoimmune diseases. Their potential extends to organ transplantation and regenerative medicine. The advancements in manufacturing techniques enable wider access and pave the path for treatments tailored as per the individual’s genetic composition.
Some of the dominant companies in the market include Lonza, Bluebird Bio, Catalent Inc., Novartis International AG, Pfizer Inc., and more.
Rise in chronic diseases.
Collaborations between academic institutions and industries.
Manufacturing scalability and cost-effectiveness.
The market has seen a surge due to collaborations between pharmaceutical giants and academic institutions. An example includes the development of Kymriah, a cancer gene therapy by Novartis and the University of Pennsylvania. There’s also a rising demand for personalized medicine leading to advanced manufacturing platforms.
CoJourney Inc. secured a $30 M Series A financing and plans on expanding its US base.
CGT Catapult unveiled new labs at the University of Edinburgh.
ElevateBio secured $401 million in a Series D financing round.
Rising incidence of chronic diseases.
Technological advancements in gene editing.
Supportive government regulations.
High manufacturing costs.
Rigorous regulatory structures.
Need for highly specialized labor.
In summary, the global cell and gene therapy manufacturing market shows strong potential and growth, fueled by technological innovations, collaboration between stakeholders, and a pressing demand for treatments for chronic diseases. However, manufacturing costs and stringent regulations may act as growth dampeners.